U.S. markets close in 3 hours 15 minutes
  • S&P 500

    4,453.06
    +4.08 (+0.09%)
     
  • Dow 30

    34,777.03
    +12.21 (+0.04%)
     
  • Nasdaq

    15,036.52
    -15.72 (-0.10%)
     
  • Russell 2000

    2,259.34
    +0.30 (+0.01%)
     
  • Crude Oil

    73.97
    +0.67 (+0.91%)
     
  • Gold

    1,752.80
    +3.00 (+0.17%)
     
  • Silver

    22.44
    -0.24 (-1.05%)
     
  • EUR/USD

    1.1726
    -0.0021 (-0.18%)
     
  • 10-Yr Bond

    1.4460
    +0.0360 (+2.55%)
     
  • GBP/USD

    1.3684
    -0.0037 (-0.27%)
     
  • USD/JPY

    110.7270
    +0.4260 (+0.39%)
     
  • BTC-USD

    42,180.88
    -1,632.79 (-3.73%)
     
  • CMC Crypto 200

    1,049.50
    -53.56 (-4.86%)
     
  • FTSE 100

    7,051.48
    -26.87 (-0.38%)
     
  • Nikkei 225

    30,248.81
    +609.41 (+2.06%)
     

Why It’s Hard to Go Wrong With Bristol Myers Stock

·3 min read
Why It’s Hard to Go Wrong With Bristol Myers Stock
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

(BMY) Squibb is a good company whose stock has underperformed the stock market. It’s not that 2021 has been unkind to Bristol Myers Squibb (BMY). Bristol Myers now trades at 8.8 times 12-month forward earnings, a discount to peers (PFE) (PFE) and (MRK) (MRK), which both trade at 12 times.